Steroid sulfatase inhibitors

Bibliography

• PASQUALINI JR, GELLY C, NGUYEN BL, VELLA C: Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. (1989) 34:155–163.
   PubMedGoogle Scholar
• REED MJ, PUROHIT A: Sulphatase inhibitors: the rationale for the development of a new endocrine therapy. Rev. Endocr. Relat. Cancer (1993) 45:51–62.
   Google Scholar
• REED MJ, PUROHIT A, HOWARTH NM, POTTER BV: Steroid sulphatase inhibitors: a new endocrine therapy. Drugs Fut. (1994) 19:673–680.
   Google Scholar
• SUZUKI T, MORIYA T, ISHIDA T, OHUCHI N, SASANO H: Intracrine mechanism of estrogen synthesis in breast cancer. Biomed. Pharmacother. (2003) 57:460–462.
   PubMed Web of Science ®Google Scholar
• NAKATA T, TAKASHIMA S, SHIOTSU Yet al.: Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J. Steroid Biochem. MoL Biol. (2003) 86:455–460.
   Google Scholar
• SUZUKI T, MIKI Y, NAKATA T et al.: Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J. Steroid Biochem. MoL Biol. (2003) 86:449–454.
   PubMed Web of Science ®Google Scholar
• PUROHIT A, WOO LWL, CHANDER SK et al.: Steroid sulfatase inhibitors for breast cancer therapy. J. Steroid Biochem. MoL Biol. (2003) 86:423–432.
   PubMed Web of Science ®Google Scholar
• UTSUMI T, YOSHIMURA N, TAKEUCHI S, MARUTA M, MAEDA K, HARADA N: Elevated steroid sulfatase expression in breast cancers. J. Steroid Biochem. MoL Biol. (2000) 73:141–145.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, NAKATA T, MIKI Yet al.: Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. (2003) 63:2762–2770.
   Google Scholar
• UTSUMI T, YOSHIMURA N, TAKEUCHI S et al.: Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. (1999) 59:377–381.
   PubMed Web of Science ®Google Scholar
• MIYOSHI Y, ANDO A, HASEGAWA S et al.: High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin. Cancer Res. (2003) 9:2288–2293.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA N, HARADA N, BUKHOLM I, KARESEN R, BORRESEN-DALE AI, KRISTENSEN VN: Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. Breast Cancer Res. (2004) 6:R46–R55.
   Web of Science ®Google Scholar
• HANKINSON SE, WILLETT WC, MANSON JE et al.: Plasma sex hormone levels and risk of breast cancer in postmenopausal women. J. NatL Cancer Inst. (1998) 90:1292–1299.
   PubMed Web of Science ®Google Scholar
• HOWARTH NM, PUROHIT A. REED MJ, POTTER BV: Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. (1994) 37:219–221.
   PubMed Web of Science ®Google Scholar
• ELGER W, SCHWARZ S, HEDDEN A, REDDERSEN G, SCHNEIDER B: Sulfamates of various estrogens - prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. MoL Biol. (1995) 55:395–403.
   PubMed Web of Science ®Google Scholar
• PAYNE AH, LAWRENCE CC, FOSTER DL, JAFFE RB: Intranuclear binding of 1713-estradiol and estrone in female ovine pituitaries following incubation with estrone sulfate. J. Biol. Chem. (1973) 248:1598–1602.
   PubMed Web of Science ®Google Scholar
• SAHM UG, WILLIAMS GJ, PUROHIT Aet al.: Development of an oral formulation for oestrone 3-0-sulphamate, a potent sulphatase inhibitor. Pharm. Sci. (1996) 2:17–20.
   Google Scholar
• ELGER W, BARTH A, HEDDEN A et ell.:Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod. FertiL Dev. (2001) 13:297–305.
   Google Scholar
• AHMED, OWEN CP, JAMES K, PATEL CK: Evidence for the mechanism of the irreversible inhibition of oestrone sulphatase (ES) by aminosulphonate based compounds. J. Steroid Biochem. MoL Biol. (2002) 80:429–440.
   PubMed Web of Science ®Google Scholar
• CHANDER SK, PUROHIT A, WOO LW, POTTER BV REED MJ: The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochem. Biophys. Res. Commun. (2004) 322:217–222.
   PubMed Web of Science ®Google Scholar
• NUSSBAUMER P, WINISKI AP, BILLICH A: Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-0-sulfamates: potent inhibitors of human steroid sulfatase. J. Med. Chem. (2003) 46:5091–5094.
   PubMed Web of Science ®Google Scholar
• IRESON CR, PARISH D, PUROHIT Aet al.: Development of a sensitive high-performance liquid chromatography method for the detection of 667COUMATE in vivo. J. Steroid Biochem. MoL Biol. (2003) 84:337–342.
   Google Scholar
• IRESON CR, CHANDER SK, PUROHIT A et al.: Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667COUMATE and its sequestration into red blood cells in rats. Br. J. Cancer (2004) 91:1399–1404.
   PubMed Web of Science ®Google Scholar
• HO YT, PUROHIT A, VICKER N et al.:Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem. Biophys. Res. Commun. (2003) 305:909–914.
   PubMed Web of Science ®Google Scholar
• ABBATE F, WINUM JY, POTTER BV et al.: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg-. Med. Chem. Lett. (2004) 14:231–234.
   PubMed Web of Science ®Google Scholar
• LLOYD MD, PEDERICK RL, NATESH R et al.: Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem J. (2005) 385:715–720.
   Google Scholar
• NUSSBAUMER P, BILLICH: Steroid sulfatase inhibitors. Med. Res. Rev. (2004) 24:529–576.
   PubMed Web of Science ®Google Scholar
• ••Key review about existing steroid sulfataseinhibitors.
   Google Scholar
• REED MJ, PUROHIT A, WOO LW, NEWMAN SP, POTTER BV: Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr. Rev. (2005) 26:171–202.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on steroid sulfataseinhibitors.
   Google Scholar
• HANSON SR, BEST MD, WONG C: Enzyme chemistry: sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Ang. Chem. (2004) 43:5736–5763.
   Google Scholar
• AHMED, OWEN CP, JAMES K, SAMPSON L, PATEL CK: Review of estrone sulfatase and its inhibitors - an important new target against hormone40.dependent breast cancer. Curr. Med. Chem. (2002) 9:263–273.
   PubMed Web of Science ®Google Scholar
• PUROHIT A, VERNON KA, WAGENAAR HUMMELINCK AE et al.: The development of A-ring modified41. analogues of oestrone-3-0-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol . Biol. (1998) 64:269–275.
   Google Scholar
• REED JE, WOO LWL, ROBINSON JJ et al.: 2-Difluoromethyloestrone 3-0-42.sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. (2004) 317:169–175.
   Google Scholar
• FISCHER DS, WOO LW MAHON MF, PUROHIT A, REED MJ, POTTER BV:43.D-Ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg. Med. Chem. (2003) 11:1685–1700.
   Google Scholar
• FISCHER DS, CHANDER SK, WOO LW et al.: Novel D-ring modified44.steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J. Steroid Biochem. MoL Biol. (2003) 84:343–349.45.
   Google Scholar
• •Highly potent steroid sulfatase inhibitors, nonoestrogenic, promising candidates for development.
   Google Scholar
• WOO LW, PUROHIT A. MALINI B, REED MJ, POTTER BV: Potent active site -directed inhibition of steroid sulphatase46.by tricyclic coumarin-based sulphamates. Chem . Biol. (2000) 7:773–791.
   Google Scholar
• SHIELDS-BOTELLA J, BONNET P et al: In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity. J. Steroid Biochem. Mot. Bia (2003) 84:327–335.
   PubMed Web of Science ®Google Scholar
• PUROHIT A, WOO LW, POTTER BV REED MJ: In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667COUMATE. Cancer Res. (2000) 60:3394–3396.
   PubMed Web of Science ®Google Scholar
• SCHREINER EP, WOLFF B, WINISKI AP, BILLICH k 6-12-(Adamantylidene)-hydroxybenzoxazolel -0-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2003) 13:4313–4316.
   PubMed Web of Science ®Google Scholar
• WOO LWL, HOWARTH NM, PUROHIT A, HEJAZ HAM, REED MJ, POTTER BVL: Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. (1998) 41:1068–1083.
   PubMed Web of Science ®Google Scholar
• WOO LW, PUROHIT A, REED MJ, POTTER BV: Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. J. Med. Chem. (1996) 39:1349–1351.
   PubMed Web of Science ®Google Scholar
• WALTER G, LIEBL R, VON ANGERER E: 2-Phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells. J. Steroid Biochem. MoL Biol. (2004) 88:409–420.
   PubMed Web of Science ®Google Scholar
• NUSSBAUMER P, LEHR P, BILLICH A: 2-Substituted 4-(thio)chromenone 6-0-sulfamates: potent inhibitors of human steroid sulfatase. J. Med. Chem. (2002) 45:4310–4320.
   PubMed Web of Science ®Google Scholar
• LI PK, MILANO S, KLUTH L, RHODES ME: Synthesis and sulfatase inhibitory activities of nonsteroidal estrone sulfatase inhibitors. J. Steroid Biochem. MoL Biol. (1996) 59:41–48.
   PubMed Web of Science ®Google Scholar
• SCHREINER EP, BILLICH A: Estrone formate: a novel type of irreversible inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2004) 14:4999–5002.
   PubMed Web of Science ®Google Scholar
• ANDERSON CJ, LUCAS LJ, WIDLANSKI TS: Molecular recognition in biological systems: phosphate esters vs. sulfate esters and the mechanism of action of steroid sulfatases. J. Am. Chem. Soc. (1995) 117:3889–3890.
   Google Scholar
• DUNCAN L, PUROHIT A, HOWARTH NM, POTTER BV REED MJ: Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. Cancer Res. (1993) 53:298–303.
   PubMed Web of Science ®Google Scholar
• HOWARTH NM, COOPER G, PUROHIT A, DUNCAN L, REED MJ, POTTER BV: Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone 3-methylthio-phos-phonate, a potent inhibitor of estrone sulfatase. Bioorg. Med. Chem. Lett. (1993) 3:313–318.
   Web of Science ®Google Scholar
• LI PK, PILLAI R, DIBBELT L: Estrone sulfate analogs as estrone sulfatase inhibitors. Steroids. (1995) 60:299–306.
   PubMed Web of Science ®Google Scholar
• HOWARTH NM, PUROHIT A, REED MJ, POTTER BV: Estrone sulfonates as inhibitors of estrone sulfatase. Steroids (1997) 62:346–350.
   PubMed Web of Science ®Google Scholar
• LI PK, PILLAI R, YOUNG BL, BENDER WH, MARTINO DM, LIN FT: Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids (1993) 58:106–111.
   PubMed Web of Science ®Google Scholar
• DIBBELT L, LI PK, PILLAI R, KNUPPEN R: Inhibition of human placental stearylsulfatase by synthetic analogs of estrone sulfate. J. Steroid. Biochem. Molec. Biol. (1994) 50:261–266.
   PubMed Web of Science ®Google Scholar
• WOO LW, LIGHTOWLER M, PUROHIT A, REED MJ, POTTER BV: Heteroatom-substituted analogues of the active-site directed inhibitor oestra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulfatase by a different mechanism. J. Steroid Biochem. MoL Biol. (1996) 57:79–88.
   PubMed Web of Science ®Google Scholar
• POIRIER D, BOIVIN RP: 17a-Alkyl- or 17-a-substituted benzy1-178-estradiols: a new family of estrone sulfatase inhibitors. Bioorg. Med. Chem. Lem (1998) 9:83–91.
   Google Scholar
• BOIVIN RP, LUU-THE LACHANCE R, LABRIE F, POIRIER D: Structure-activity relationships of 17a-derivatives of estradiol as inhibitors of steroid sulfatase. J. Med. Chem. (2000) 43:4465–4478.
   PubMed Web of Science ®Google Scholar
• CIOBANU LC, BOIVIN RP, LUU -THE V, POIRER D: 38-Sulfamate derivatives of C19 and C21 steroids bearing a t-butylbenzyl or a benzyl group: synthesis and evaluation as non-estrogenic and non-androgenic steroid sulfatase inhibitors. Enzyme Inhib. Med. Chem. (2003) 18:15–26.
   PubMed Web of Science ®Google Scholar
• HORVATH A, NUSSBAUMER P, WOLFF B, BILLICH A: 2-(1-Adamanty1)-4-(thio)chromenone-6-carboxylic acids: potent reversible inhibitors of human steroid sulfatase. J. Med. Chem. (2004) 47:4268–4276.
   PubMed Web of Science ®Google Scholar
• JOTTEN P, SCHUMANN W, HARTL A et al.: A novel type of nonsteroidal estrone sulfatase inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1339–1342.
   PubMed Web of Science ®Google Scholar
• LEE W, DEROME M, DEBEAR J et al.: Aryl piperazines: a new class of steroid sulfatase inhibitors for the treatment of hormone-dependent breast cancer. Abstracts of Papers, 226th ACS National Meeting. NY, USA (7–11 September 2003) MEDI–301.
   Google Scholar
• NUSSBAUMER P, GEYL D, HORVATH A, LEHR P, WOLFF B, BILLICH A Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2003) 13:3673–3677.
   PubMed Web of Science ®Google Scholar
• •Novel chemotype of reversible, competitive steroid sulfatase inhibitors.
   Google Scholar
• POIRIER D, CIOBANU LC, MALTAIS R: Steroid sulfatase inhibitors. Expert Opin. Ther. Patents (1999) 9:1083–1099.
   Web of Science ®Google Scholar
• NUSSBAUMER P, BILLICH A: Steroid sulfatase inhibitors. Expert Opin. Ther. Patents (2003) 13:605–625.
   Web of Science ®Google Scholar
• SMITH HJ, NICHOLLS PJ, SIMONS C, LAIN RL: Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Expert Opin. Ther. Patents (2001) 11:789–1308.
   Web of Science ®Google Scholar
• WINUM JY, SCOZZAFAVA A, MONTERO JL, SUPURAN CT: Therapeutic applications of sulfamates. Expert Opin. Ther Patents (2004) 14:1273–1308.
   Web of Science ®Google Scholar
• LEESE MP, NEWMAN SP, PUROHIT A, REED MJ, POTTER BV: 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumor agents. Bioorg. Med. Chem. Lett. (2004) 13:3135–3138.
   Google Scholar
• HUANG P, FENG L, OLDHAM EA, KEATING MJ, PLUNKETT W: Superoxide dismutase as a target for the selective killing of cancer cells. Nature (2000) 407:390–395.
   PubMed Web of Science ®Google Scholar
• CIOBANU LC, LUU-THE V, MARTEL C, LABRIE F, POIRIER D: Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res. (2003) 63:6442–6446.
   PubMed Web of Science ®Google Scholar
• CIOBANU LC, POIRIER D: Solid-phase parallel synthesis of 17a-substituted estradiol sulfamate and phenol libraries using the multidetachable sulfamate linker. J. Comb. Chem. (2003) 5:429–440.
   PubMedGoogle Scholar
• OKADA M, NAKAGAWA T, IWASHITA S, TAKEGAWA S, FUJII T, KOIZUMI N: Development of novel steroid sulfatase inhibitors I. Synthesis and biological evaluation of biphenyl-4-0-sulfamates. J. Steroid Biochem. MoL Biol. (2003) 87:141–148.
   Google Scholar
• SAITO T, KINOSHITA S, FUJII T et al.: Development of novel steroid sulfatase inhibitors II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats. J. Steroid Biochem. MoL BioL (2004) 88:167–173.
   Google Scholar
• CIOBANU LC, LUU-THE V, POIRER D: Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors. J. Steroid Biochem. MoL Biol. (2002) 80:339–353.
   PubMed Web of Science ®Google Scholar
• PATEL CK, OWEN CP, AHMED S: The design, synthesis, and in vitro biochemical evaluation of a series of esters of 4-Raminosulfonyl)oxylbenzoate as novel and highly potent inhibitors of estrone sulfatase. Biochem. Biophys. Res. Commun. (2003) 307:778–781.
   PubMed Web of Science ®Google Scholar
• WOLFF B, BILLICH A. BRUNOWSKY W et al.: Microtiter plate cellular assay for human steroid sulfatase with fluorescence readout. AnaL Biochem. (2003) 318:276–284.
   Google Scholar
• LEHR P, BILLICH k WOLFF B, NUSSBAUMER P: N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2005) 15:1235–1238.
   PubMed Web of Science ®Google Scholar
• STANWAY S, PUROHIT A, WOO LW et al.: First phase I trial of a steroid sulfatase inhibitor in breast cancer. J. Clin. OncoL (2004) 22:(Supp1.145) Abstract 64S.
   Google Scholar
• •Short report of first clinical studies using 667COUMATE in breast cancer patients.
   Google Scholar